Anebulo Pharmaceuticals, Inc. ANEB
0.26 USD -0.03 (-9.31%)
At closeNov 10, 2026, 4:00 PM EST
0.38 +0.12 +45.21%
After hours · Nov 10, 4:00 PM ET
0.8699 Day range 0.8699
0.001 52-week range 2.49
- YTD
- -73.96%
- 1 year
- -88.86%
- Market cap
- 10.73M
- EPS (ttm)
- -0.19
- Shares out
- 25.93M
- Forward P/E
- -2.49
- YTD return
- -73.96%
- 1-year return
- -88.86%
- Volume
- 100
- Avg volume
- 473
- Open
- 0.8699
- Previous close
- 0.29
- Day's range
- 0.8699 – 0.8699
- 52-week range
- 0.001 – 2.49
- Beta
- -1.01
- Price target
- 8.00 (+2941.8%)
- Earnings date
- Feb 11, 2025
No chart data for this range yet.
Key statistics
- Enterprise value
- 36.32M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 11.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.18M
- Total cash
- 3.09M
- Total debt
- 0
- Return on equity
- -113.80%
- Short % of float
- 0.28%
- 50-day average
- 1.60
- 200-day average
- 2.14
Analyst view
Price target (mean) 8.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.08.
Financials — quick view
ANEB Revenue — quarterly 0
ANEB Net income — quarterly -2.00M
ANEB EPS — quarterly -0.05
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.08 | — | — |
| Sep 25, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Sep 25, 2024 | Jun 1, 2024 | 0.00 | -0.05 | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.11 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -0.11 | -0.06 | +0.05 | +45.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Oct 1, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Oct 3, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Sep 25, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 21, 2023 | Maxim Group | init | — | Buy |
| Sep 18, 2023 | HC Wainwright & Co. | init | — | Buy |
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anebulo.com
News
Anebulo Pharmaceuticals (ANEB) to Announce Earnings on Wednesday 
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Anebulo Pharmaceuticals Q2 EPS $(0.05) Beats $(0.13) Estimate 
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates 
12 Health Care Stocks Moving In Friday's Intraday Session 
Anebulo Pharmaceuticals Voluntarily Delisting Common Shares From Nasdaq, Effective Feb. 27 
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC 
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next? 
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next?
Your note
Sign in to keep a note on ANEB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ENGLISH ARON R | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Dec 17, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| 22NW, LP | 20.69% | 5,366,290 | 8.69M | Sep 29, 2024 |
| LVW Advisors, LLC | 2.47% | 641,039 | 1.04M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 1.97% | 511,073 | 827.94K | Sep 29, 2024 |
| Morgan Stanley | 1.54% | 399,219 | 646.73K | Sep 29, 2024 |
| Ikarian Capital, LLC | 0.61% | 157,862 | 255.74K | Sep 29, 2024 |
| Vanguard Group Inc | 0.59% | 154,036 | 249.54K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.47% | 121,000 | 196.02K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.21% | 53,431 | 86.56K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.13% | 33,036 | 53.52K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 14,728 | 23.86K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 11,840 | 19.18K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 4,108 | 6.65K | Oct 30, 2024 |